PF4 and autoimmune polyendocrinopathy: Data analysis of anti-β2-GPI/PF4 antibody prevalence according to demographic and clinical manifestations also revealed a significant association between the onset of APS before the age of 35 and anti-β2-GPI/PF4 antibody positivity (p = 0.01) (Figure 3).